arterial diseases

Spirit II explores long-term performance of XIENCE V stent

harminka — Mon, 31 Mar 2008 12:18:16 -0500

Early results of the SPIRIT II study showed that the XIENCE V stent was superior to the Taxus stent in six-month findings on angiography and trended better on one-year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus-coated XIENCE V stent may continue to hold a clinical edge over its paclitaxel-coated competitor.

Investigational anti-restenosis drug pimecrolimus disappoints

harminka — Mon, 31 Mar 2008 11:37:35 -0500

A new medication that researchers had hoped would reduce the risk of arterial renarrowing after stenting has turned in a disappointing performance in a multicenter clinical trial, but the multi-reservoir stent that was used to deliver the drug is still considered promising.

Setting up a roadblock for atherosclerosis

harminka — Fri, 08 Feb 2008 13:05:17 -0600

Treatment with the antibiotic myriocin can halt the growth of established arterial plaques in mice, researchers report.

Atherothrombosis associated with high rates of cardiovascular events

harminka — Wed, 21 Mar 2007 12:00:21 -0500

Patients with arterial disease have relatively high rates of experiencing a cardiovascular event (such as heart attack, stroke or cardiovascular death) within one year, and these increase with the number of arterial locations afflicted, according to a large, international study in the March 21 issue of JAMA.